Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07762573

Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective Study

To evaluate the utility of DCR-derived parameters for identifying dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of disease progression in COPD.

Recruiting

Interested in participating?

Request Info

Key information

Age range

30 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, 510400, China

Location status: Recruiting

Location contact

Laiyu Liu, Professor

CONTACT

[email protected]

+86 13632102245

About this study

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Approximately 100 million people in China have COPD, yet the early diagnosis rate remains below 13%. This multicenter retrospective study will collect previously acquired dynamic chest radiography (DCR) images, pulmonary function test results, chest computed tomography images, symptom scores, clinical data, and follow-up outcomes from participating centers. A standardized multicenter retrospective DCR-COPD database will be established to systematically evaluate the utility of DCR-derived parameters for characterizing dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of COPD progression. The study will also provide a foundation for model development and subsequent prospective multicenter validation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 30-85 years.
  • Male or female.
  • Patients who underwent pulmonary function testing and dynamic chest radiography at the hospital.

Exclusion criteria

  • Incomplete medical records.
  • Considered unsuitable for inclusion in the study at the investigator's discretion.

Treatment and study plan

Primary outcomes

  1. Exacerbation/respiratory history and event

    Time frame: At Baseline

    Measurement of disease control and burden

  2. FEV1 %

    Time frame: At Baseline

    Measurement of lung function

  3. FEV1 /FVC

    Time frame: At Baseline

    Measurement of lung function

  4. Emphysema

    Time frame: At Baseline

    Measurement of chest CT

  5. diaphragm movement

    Time frame: At Baseline

    Measurement of Dynamic chest radiograph

  6. lung field area

    Time frame: At Baseline

    Measurement of Dynamic chest radiograph

  7. lung field area change rate

    Time frame: At Baseline

    Measurement of Dynamic chest radiograph

  8. CAT

    Time frame: At Baseline

    Measurement of questionnaires

  9. SGRQ

    Time frame: At Baseline

    Measurement of questionnaires

  10. mMRC

    Time frame: At Baseline

    Measurement of questionnaires

  11. Smoking history and status

    Time frame: At Baseline

    Risk factors of COPD development or lung function decline

Study contacts

Contact information is provided by the study sponsor or research team.

Dong Yu

CONTACT

[email protected]

+86 15625868995

Laiyu Liu, Professor

CONTACT

[email protected]

+86 13632102245

Sponsors and collaborators

Lead sponsor

Nanfang Hospital, Southern Medical University

Other

Collaborators

  • Qingyuan People's Hospital
  • The First Affiliated Hospital of Guangzhou Medical University

Registry information

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
Aug 13, 2026
Registry last updated
Aug 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.